The effects of alteplase 3 to 6 hours after stroke in the EPITHET-DEFUSE combined dataset: post hoc case-control study

Toshiyasu Ogata, Soren Christensen, Yoshinari Nagakane, Henry Hin Kui Ma, Bruce C V Campbell, Leonid Churilov, Maarten G Lansberg, Matus Straka, Deidre Anne De Silva, Michael Mlynash, Roland Bammer, Jean-Marc Olivot, Patricia M Desmond, Gregory W Albers, Stephen M Davis, Geoffrey Donnan

Research output: Contribution to journalArticleResearchpeer-review

48 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE: Two phase 2 studies of alteplase in acute ischemic stroke 3 to 6 hours after onset, Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET; a randomized, controlled, double-blinded trial), and Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution Study (DEFUSE; open-label, treatment only) using MR imaging-based outcomes have been conducted. We have pooled individual patient data from these to assess the response to alteplase. The primary hypothesis was that alteplase would significantly attenuate infarct growth compared with placebo in mismatch-selected patients using coregistration techniques. METHODS: The EPITHET-DEFUSE study datasets were pooled while retaining the original inclusion and exclusion criteria. Significant hypoperfusion was defined as a Tmax delay >6 seconds), and coregistration techniques were used to define MR diffusion-weighted imaging/perfusion-weighted imaging mismatch. Neuroimaging, parameters including reperfusion, recanalization, symptomatic intracerebral hemorrhage, and clinical outcomes were assessed. Alteplase and placebo groups were compared for the primary outcome of infarct growth as well for secondary outcome measures. RESULTS: From 165 patients with adequate MR scans in the EPITHET-DEFUSE pooled data, 121 patients (73.3 ) were found to have mismatch. For the primary outcome analysis, 60 patients received alteplase and 41 placebo. Mismatch patients receiving alteplase had significantly attenuated infarct growth compared with placebo (P=0.025). The reperfusion rate was also increased (62.7 vs 31.7 ; P=0.003). Mortality and clinical outcomes were not different between groups. CONCLUSIONS: The data provide further evidence that alteplase significantly attenuates infarct growth and increases reperfusion compared with placebo in the 3- to 6- hour time window in patients selected based on MR penumbral imaging.
Original languageEnglish
Pages (from-to)87 - 93
Number of pages7
JournalStroke
Volume44
Issue number1
DOIs
Publication statusPublished - 2013

Cite this